Single dose aprotinin in routine cardiac surgery

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Hemostasis

Background:

• High-dose aprotinin effectively reduces bleeding during cardiopulmonary bypass (CPB), especially in high-risk patients.
• The efficacy of lower-dose or single-dose aprotinin regimens in routine cardiac surgery remains uncertain.

Purpose of the Study:

• To evaluate the effectiveness of a single, low dose of aprotinin administered during CPB in reducing blood loss and transfusion requirements in low-risk adult patients undergoing their first cardiac procedure.

Main Methods:

• A randomized, prospective, double-blinded study compared a single dose of aprotinin with a placebo in low-risk adults undergoing primary cardiac surgery with CPB.
• Blood loss and the use of transfused blood products were assessed as primary endpoints.
• The study also analyzed the impact of aspirin use on bleeding and transfusion outcomes.

Main Results:

• Aprotinin treatment resulted in a significant reduction in red blood cell transfusions.
• However, there was no significant improvement in overall blood loss or the use of other blood components in the aprotinin group compared to placebo.
• Aspirin use was associated with significantly increased blood loss and blood product usage in both treatment and control groups.

Conclusions:

• A single, low dose of aprotinin is not an effective strategy for improving hemostasis or reducing overall bleeding and blood component use in routine cardiac surgery following CPB.
• The findings suggest that the benefits of aprotinin in CPB may be dose-dependent, with lower doses lacking efficacy in this setting.